

• **Name:** Seok Jin KIM

• **Current Position:** Professor

Division of Hematology-Oncology, Department of Medicine

Samsung Medical Center, Sungkyunkwan University School of Medicine

81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea

Tel: 82-2-3410-1766, Fax: 82-2-3410-1754, E-mail: [kstw@skku.edu](mailto:kstw@skku.edu)

• **Country:** Republic of Korea

• **Educational Background:**

1988. 3 – 1994. 2 Bachelor's degree, College of Medicine, Korea University, Seoul, Korea

1995. 9 – 1997. 8 Master's degree, Graduate School of Korea University, Seoul, Korea

1997. 9 – 2003. 2 Ph.D., Graduate School of Korea University, Seoul, Korea

• **Professional Experiences:**

1994. 3 – 1995. 2 Intern, Korea University Guro Hospital, Seoul, Korea

1995. 3 – 1999. 2 Residency of Internal medicine, Korea University Anam Hospital, Seoul, Korea

1999. 4 – 2002. 3 Officer in Army of Obligation

2002. 4 – 2003. 4 Fellowship of Hematology/Oncology, Korea University Medical Center, Seoul, Korea

2003. 5 – 2004. 8 Postdoctoral fellow, Medicine-Oncology, Duke University Medical Center, NC, USA

2004. 9 – 2008. 1 Assistant professor, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea

2008. 2 – 2014. 3 Associate professor, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

2014. 4 - Professor, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

• **Professional Organizations:**

Korean Association of Internal Medicine, Korean Cancer Association

Korean Society of Hematology

Korean Society of Blood and Marrow Transplantation

American Society of Hematology

• **Main Scientific Publications:**

**Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study.**

**Kim SJ**, Lim JQ, Laurensia Y, Cho J, Yoon SE, Lee JY, Ryu KJ, Ko YH, Koh Y, Cho D, Lim ST, Beck Enemark M, D'amore F, Bjerre M, Ong CK, Kim WS.

**Blood. 2020 Aug 7:** blood.2020007247. doi: 10.1182/blood.2020007247.

**Serum-Derived Exosomal MicroRNA Profiles Can Predict Poor Survival Outcomes in Patients with Extranodal Natural Killer/T-Cell Lymphoma.**

Ryu KJ, Lee JY, Choi ME, Yoon SE, Cho J, Ko YH, Shim JH, Kim WS, Park C, **Kim SJ**.

**Cancers (Basel). 2020 Nov 27;12(12):3548.**

**A comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective cohort study.**

Yoon SE, Eun Y, Huh K, Chung CR, Yoo IY, Cho J, Cho D, Ko YH, Park S, Kim WS, **Kim SJ**.

**Ann Hematol. 2020 Sep;99(9):2095-2104.**

**Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.**

Cho I, Lee H, Yoon SE, Ryu KJ, Ko YH, Kim WS, **Kim SJ.**

**BMC Cancer. 2020 Feb 13;20(1):120**

**Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma.**

**Kim SJ,** Yoon DH, Kang HJ, Hong JY, Lee HS, Oh SY, Shin HJ, Kong JH, Yi JH, Sakamoto K, Ko YH, Huh J, Lee SS, Takeuchi K, Shin DY, Suh C, Kim WS.

**BMC Cancer. 2019 Nov 10;19(1):1080**

**Vitamin D deficiency is associated with inferior survival of patients with extranodal natural killer/T-cell lymphoma.**

**Kim SJ,** Shu C, Ryu KJ, Kang D, Cho J, Ko YH, Lee SY, Guallar E, Zhao W, Kim WS.

**Cancer Sci. 2018 Dec;109(12):3971-3980.**

**A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis.**

**Kim SJ,** Yoon DH, Jaccard A, Chng WJ, Lim ST, Hong H, Park Y, Chang KM, Maeda Y, Ishida F, Shin DY, Kim JS, Jeong SH, Yang DH, Jo JC, Lee GW, Choi CW, Lee WS, Chen TY, Kim K, Jung SH, Murayama T, Oki Y, Advani R, d'Amore F, Schmitz N, Suh C, Suzuki R, Kwong YL, Lin TY, Kim WS

**Lancet Oncology 2016 Mar; 17(3): 389-400.**

**A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas.**

**Kim SJ,** Shin DY, Kim JS, Yoon DH, Lee WS, Lee H, Do YR, Kang HJ, Eom HS, Ko YH, Lee SH, Yoo HY, Hong M, Suh C, Kim WS

**Ann Oncology 2016 Apr; 27 (4): 712-8.**

**Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin.**

Kim SJ, Kim JH, Ki CS, Ko YH, Kim JS, Kim WS

**Ann Oncology 2016 Mar; 27 (3): 508-13.**

**Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis.**

Kim SJ, Choi JY, Hyun SH, Ki CS, Oh D, Ahn YC, Ko YH, Choi S, Jung SH, Khong PL, Tang T, Yan X, Lim ST, Kwong YL, Kim WS; Asia Lymphoma Study Group

**Lancet Haematology 2015 Feb; 2 (2): e66-74.**

**A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma.**

Yoo HY, Sung MK, Lee SH, Kim S, Lee H, Park S, Kim SC, Lee B, Rho K, Lee JE, Cho KH, Kim W, Ju H, Kim J, Kim SJ, Kim WS, Lee S, Ko YH

**Nature Genetics 2014 Apr; 46 (4): 371-5.**

**Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone.**

Kim SJ, Kang HJ, Kim JS, Oh SY, Choi CW, Lee SI, Won JH, Kim MK, Kwon JH, Mun YC, Kwak JY, Kwon JM, Hwang IG, Kim HJ, Park J, Oh S, Huh J, Ko YH, Suh C, Kim WS

**Blood 2011 Feb 10; 117 (6): 1958-65.**

**Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: Results from a prospective multicenter phase II study.**

Kim SJ, Lee JW, Jung CW, Min CK, Cho B, Shin HJ, Chung JS, Kim H, Lee WS, Joo YD, Yang DH, Kook H, Kang HJ, Ahn HS, Yoon SS, Sohn SK, Min YH, Min WS, Park HS, Won JH

**Haematologica 2010 Nov; 95 (11): 1935-42.**

**When do we need central nervous system prophylaxis in the patients with extranodal**

**NK/T cell lymphoma, nasal type?**

**Kim SJ**, Oh SY, Hong JY, Chang MH, Lee DH, Huh J, Ko YH, Ahn YC, Kim HJ, Suh C, Kim K, Kim WS

**Ann Oncology 2010 May; 21 (5): 1058-63.**

**Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed stage IE/IIIE nasal extranodal NK/T cell lymphoma: CISL study**

**Kim SJ**, Kim K, Kim BS, Kim CY, Suh C, Huh J, Lee SW, Kim JS, Cho J, Lee GW, Kang KM, Eom HS, Pyo HR, Ahn YC, Ko YH, Kim WS

**Journal of Clinical Oncology 2009 Dec 10; 27 (35): 6027-6032**